However, afatinib has shown some activity in other populations of patients with metastatic breast cancer, including patients with triple-negative breast cancer who had progressed following three or fewer lines of chemotherapy [35] and in combination with letrozole in patients with estrogen receptor-positive metastatic breast cancer who had progressed on letrozole monotherapy [36]. Here, ESR1 is linked to triple-negative breast carcinoma.